Literature DB >> 30328074

Acinetobacter baumannii meningitis in children: a case series and literature review.

Jiying Xiao1, Chenmei Zhang2, Sheng Ye3.   

Abstract

INTRODUCTION: The incidence of Acinetobacter baumannii meningitis, which typically occurs after neurosurgery, has increased in recent years. Pediatric Acinetobacter baumannii meningitis due to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has important clinical significance.
METHODOLOGY: We retrospectively reviewed the clinical course and outcome of nine cases of meningitis due to Acinetobacter baumannii in children and reviewed the relevant literature.
RESULTS: Seven patients had a history of neurosurgery, and the average time from the first surgery to cerebrospinal fluid (CSF) culture in these seven patients was 23.71 ± 17.43 days. Of all nine patients, four patients showed MDR isolates, two showed XDR isolates, and one showed pan-drug-resistant (PDR) isolates. Three patients received an intrathecal injection of amikacin. Two patients received intravenous colistin (5 mg/kg), and one received polymyxin B (2 mg/kg). The mean hospitalization duration was 39.44 days. Four patients eventually died: two with MDR Acinetobacter, one with PDR Acinetobacter, and one with susceptible Acinetobacter. Two of them still had positive CSF cultures at death.
CONCLUSION: Acinetobacter baumannii meningitis is usually associated with neurosurgery and the placement of foreign material, and it usually has a high mortality. Intrathecal or intraventricular polymyxin administration is expected to be an effective choice for meningitis but requires further study.

Entities:  

Keywords:  Acinetobacter baumannii; Children; Polymyxin; Postoperative meningitis

Mesh:

Substances:

Year:  2018        PMID: 30328074     DOI: 10.1007/s15010-018-1234-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  31 in total

1.  Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.

Authors:  P Fernandez-Viladrich; X Corbella; L Corral; F Tubau; A Mateu
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Acinetobacter baumannii pseudomeningitis.

Authors:  William M Gusten; Eric A Hansen; Burke A Cunha
Journal:  Heart Lung       Date:  2002 Jan-Feb       Impact factor: 2.210

3.  Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

Authors:  M E Jiménez-Mejías; C Pichardo-Guerrero; F J Márquez-Rivas; D Martín-Lozano; T Prados; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-19       Impact factor: 3.267

Review 4.  Acinetobacter species: which do we mean?

Authors:  L Dijkshoorn; J van der Toorn
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

5.  HERELLEA MENINGITIS FOLLOWING VENTRICULOGRAPHY.

Authors:  E B HOOK; J M AASE
Journal:  Am J Dis Child       Date:  1964-11

6.  Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E.

Authors:  Mony Benifla; Gideon Zucker; Avi Cohen; Michael Alkan
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

7.  Practice guidelines for the management of bacterial meningitis.

Authors:  Allan R Tunkel; Barry J Hartman; Sheldon L Kaplan; Bruce A Kaufman; Karen L Roos; W Michael Scheld; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2004-10-06       Impact factor: 9.079

Review 8.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.

Authors:  Robert A Bonomo; Dora Szabo
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

9.  Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review.

Authors:  John Ng; Iain B Gosbell; John A Kelly; Michael J Boyle; John K Ferguson
Journal:  J Antimicrob Chemother       Date:  2006-08-17       Impact factor: 5.790

10.  Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis.

Authors:  Anne-Marie Korinek; Thomas Baugnon; Jean-Louis Golmard; Rémy van Effenterre; Pierre Coriat; Louis Puybasset
Journal:  Neurosurgery       Date:  2006-07       Impact factor: 4.654

View more
  6 in total

Review 1.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Development and Validation of a Model for Predicting the Risk of Death in Patients with Acinetobacter baumannii Infection: A Retrospective Study.

Authors:  Hui Zhang; Yayun Zhao; Yahong Zheng; Qinxiang Kong; Na Lv; Yanyan Liu; Dongmei Zhao; Jiabin Li; Ying Ye
Journal:  Infect Drug Resist       Date:  2020-08-10       Impact factor: 4.003

3.  Comparative analysis of carbapenemases, RND family efflux pumps and biofilm formation potential among Acinetobacter baumannii strains with different carbapenem susceptibility.

Authors:  Yanpeng Zhang; Bing Fan; Yong Luo; Zhiyuan Tao; Yongbo Nie; Yongtao Wang; Fanglin Ding; Yanwu Li; Dayong Gu
Journal:  BMC Infect Dis       Date:  2021-08-20       Impact factor: 3.090

4.  First Description of the Composition and the Functional Capabilities of the Skin Microbial Community Accompanying Severe Scabies Infestation in Humans.

Authors:  Charlotte Bernigaud; Martha Zakrzewski; Sara Taylor; Pearl M Swe; Anthony T Papenfuss; Kadaba S Sriprakash; Deborah Holt; Olivier Chosidow; Bart J Currie; Katja Fischer
Journal:  Microorganisms       Date:  2021-04-23

Review 5.  Convergence of Biofilm Formation and Antibiotic Resistance in Acinetobacter baumannii Infection.

Authors:  Subhasree Roy; Goutam Chowdhury; Asish K Mukhopadhyay; Shanta Dutta; Sulagna Basu
Journal:  Front Med (Lausanne)       Date:  2022-03-24

6.  Efflux Pump Overexpression Profiling in Acinetobacter baumannii and Study of New 1-(1-Naphthylmethyl)-Piperazine Analogs as Potential Efflux Inhibitors.

Authors:  Morgane Choquet; Elodie Lohou; Etienne Pair; Pascal Sonnet; Catherine Mullié
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.